Solifenacin (rINN), marketed as solifenacin succinate under the trade name Vesicare, is a urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with urge incontinence. [Wikipedia]
Taking into account the above-mentioned characteristics, two accurate, simple, precise, economical, and rapid, visible spectrophotometric assay methods were developed, for the quantitative estimation of solifenacin succinate in tablet dosage forms.
Hence, these developed methods could be used for the routine estimation of solifenacin succinate in tablet formulations.
At the time of her visit to our pain clinic, she was receiving Propranolol HCl 20 mg, Mirtazapine 30 mg and Tramadol HCl 50 mg twice a day, along with Buspirone HCl 15 mg, solifenacin succinate 5 mg, Mefenamic Acid 250 mg, ethyl loflazepate 1 mg and sodium tianeptine 12.5 mg daily.
Although there are other medical alternatives such as Darifenacin, Trospium Chloride, and solifenacin succinate is available, their safety in children is not known.
solifenacin succinate launched in 2006 is the first available anticholinergic agent having higher selectivity for M3 receptor subtype approved for patients with OAB symptoms in Japan .
Indication of additional administration of solifenacin succinate was clinically decided based on experience of each urologist by concerning comorbidity, maximum flow rate (Qmax), postvoid residual urine volume (PVR), and so forth to minimize development of acute urinary retention.
solifenacin succinate, a newly developed muscarinic receptor antagonist, could inhibit carbachol-induced intracellular Ca2+ mobilization in guinea pig smooth muscle cells and murine submandibular gland cells in vitro.
solifenacin succinate and the other antimuscarinic drugs, such as Darifenacin and Oxybutynin chloride, which have higher affinity for muscarinic M3 receptor, are also reported to inhibit an increase in intracellular Ca2+ levels in rat salivary gland cells induced by Carbachol stimulation.
Newer antimuscarinic agents include the M3 selective antagonists, Darifenacin (Enablex®) and solifenacin (Vesicare) and the relatively non-subtype selective antagonists, Tolterodine (Detrol®) and its related compound Fesoterodine (Toviaz®), which has only been recently introduced.